×
About 1,335 results

ALLMedicine™ Metastatic Bone Disease Center

Research & Reviews  631 results

Quality of life and pain in patients with metastatic bone disease from solid tumors tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893880
BMC Cancer; Ribi K, Thürlimann B et. al.

Feb 20th, 2021 - Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. Th...

The clinical effectiveness of reconstructing 18F-sodium fluoride PET/CT bone using Baye...
https://doi.org/10.1259/bjr.20210043
The British Journal of Radiology; Usmani S, Ahmed N et. al.

Feb 11th, 2021 - A new Bayesian penalized likelihood reconstruction algorithm for positron emission tomography (PET) (Q.Clear) is now in clinical use for fludeoxyglucose (FDG) PET/CT. However, experience with non-FDG tracers and in special patient populations is l...

Is a single dose of preoperative antibiotic therapy effective for patients treated with...
https://doi.org/10.1007/s12306-020-00692-6 10.1200/JCO.1991.9.3.509 10.1302/0301-620X.83B4.0830471 10.1302/0301-620X.82B1.0820062 10.1302/0301-620X.84B4.0840521 10.1097/01.blo.0000223978.36831.39 10.1007/s11999-011-2038-0 10.1155/2016/9079041 10.1302/0301-620X.98B6.37417 10.1136/bmjopen-2012-002197 10.1302/0301-620X.89B12.19481 10.2106/JBJS.J.00834 10.2106/JBJS.C.01222 10.1097/00003086-200202000-00022 10.1186/1471-2474-13-91 10.1302/0301-620X.91B1.20448 10.1155/2015/428986 10.1007/s00590-016-1857-9 10.1002/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W 10.1007/s11999-014-3736-1 10.1302/0301-620X.89B10.19233 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 10.1080/00016470410001708270 10.1016/j.suronc.2013.02.008 10.1016/j.jse.2011.06.019 10.1007/s00402-007-0464-y 10.3109/17453674.2013.788437 10.1302/0301-620X.85B5.13838 10.1016/S0883-5403(06)80087-2 10.1097/01.blo.0000229332.91158.05 10.1007/s11999-013-2842-9 10.1007/978-3-540-77960-5_7 10.1007/s00264-003-0429-x 10.1097/01.blo.0000079264.91782.83 10.1302/0301-620X.79B1.0790031 10.1155/2013/821650 10.1302/0301-620X.78B4.0780652 10.3346/jkms.1990.5.4.205 10.1302/0301-620X.91B11.21996 10.1302/0301-620x.98b6.37417 10.1016/S1051-0443(98)70267-2 10.1302/0301-620x.101b5.bjj-2018-1106.r1 10.1086/421095 10.1111/j.1445-2197.1998.tb04785.x 10.1016/j.diagmicrobio.2010.10.025 10.1007/s11999-010-1454-x 10.1302/0301-620X.89B4.18631 10.1007/s12306-019-00595-1
Musculoskeletal Surgery; Kiran M, Alsousou J et. al.

Jan 5th, 2021 - Purpose The timing and number of doses of antibiotics required for megaendoprosthetic replacement (MPR) in metastatic bone disease (MBD) is a matter of debate. The aim of our study is to present the results of a prospective cohort of MPR for MBD r...

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metasta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747039
JAMA Oncology; Van Poznak CH, Unger JM et. al.

Dec 17th, 2020 - Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. To define the cumulative incidence of ONJ at 3 years in patients receiving ...

Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastati...
https://doi.org/10.1111/odi.13746
Oral Diseases REFERENCES; Van Poznak C, Reynolds EL et. al.

Dec 4th, 2020 - A case-control study was performed to define clinical and genetic risk factors associated with osteonecrosis of the jaw in patients with metastatic cancer treated with bisphosphonates. Clinical data and tissues were collected from patients treated...

see more →

Clinicaltrials.gov  667 results

Quality of life and pain in patients with metastatic bone disease from solid tumors tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893880
BMC Cancer; Ribi K, Thürlimann B et. al.

Feb 20th, 2021 - Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. Th...

The clinical effectiveness of reconstructing 18F-sodium fluoride PET/CT bone using Baye...
https://doi.org/10.1259/bjr.20210043
The British Journal of Radiology; Usmani S, Ahmed N et. al.

Feb 11th, 2021 - A new Bayesian penalized likelihood reconstruction algorithm for positron emission tomography (PET) (Q.Clear) is now in clinical use for fludeoxyglucose (FDG) PET/CT. However, experience with non-FDG tracers and in special patient populations is l...

Is a single dose of preoperative antibiotic therapy effective for patients treated with...
https://doi.org/10.1007/s12306-020-00692-6 10.1200/JCO.1991.9.3.509 10.1302/0301-620X.83B4.0830471 10.1302/0301-620X.82B1.0820062 10.1302/0301-620X.84B4.0840521 10.1097/01.blo.0000223978.36831.39 10.1007/s11999-011-2038-0 10.1155/2016/9079041 10.1302/0301-620X.98B6.37417 10.1136/bmjopen-2012-002197 10.1302/0301-620X.89B12.19481 10.2106/JBJS.J.00834 10.2106/JBJS.C.01222 10.1097/00003086-200202000-00022 10.1186/1471-2474-13-91 10.1302/0301-620X.91B1.20448 10.1155/2015/428986 10.1007/s00590-016-1857-9 10.1002/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W 10.1007/s11999-014-3736-1 10.1302/0301-620X.89B10.19233 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 10.1080/00016470410001708270 10.1016/j.suronc.2013.02.008 10.1016/j.jse.2011.06.019 10.1007/s00402-007-0464-y 10.3109/17453674.2013.788437 10.1302/0301-620X.85B5.13838 10.1016/S0883-5403(06)80087-2 10.1097/01.blo.0000229332.91158.05 10.1007/s11999-013-2842-9 10.1007/978-3-540-77960-5_7 10.1007/s00264-003-0429-x 10.1097/01.blo.0000079264.91782.83 10.1302/0301-620X.79B1.0790031 10.1155/2013/821650 10.1302/0301-620X.78B4.0780652 10.3346/jkms.1990.5.4.205 10.1302/0301-620X.91B11.21996 10.1302/0301-620x.98b6.37417 10.1016/S1051-0443(98)70267-2 10.1302/0301-620x.101b5.bjj-2018-1106.r1 10.1086/421095 10.1111/j.1445-2197.1998.tb04785.x 10.1016/j.diagmicrobio.2010.10.025 10.1007/s11999-010-1454-x 10.1302/0301-620X.89B4.18631 10.1007/s12306-019-00595-1
Musculoskeletal Surgery; Kiran M, Alsousou J et. al.

Jan 5th, 2021 - Purpose The timing and number of doses of antibiotics required for megaendoprosthetic replacement (MPR) in metastatic bone disease (MBD) is a matter of debate. The aim of our study is to present the results of a prospective cohort of MPR for MBD r...

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metasta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747039
JAMA Oncology; Van Poznak CH, Unger JM et. al.

Dec 17th, 2020 - Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. To define the cumulative incidence of ONJ at 3 years in patients receiving ...

Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastati...
https://doi.org/10.1111/odi.13746
Oral Diseases REFERENCES; Van Poznak C, Reynolds EL et. al.

Dec 4th, 2020 - A case-control study was performed to define clinical and genetic risk factors associated with osteonecrosis of the jaw in patients with metastatic cancer treated with bisphosphonates. Clinical data and tissues were collected from patients treated...

see more →

News  37 results

Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ
https://www.medscape.com/viewarticle/913958

Jun 4th, 2019 - CHICAGO — New data highlight the risk for osteonecrosis of the jaw (ONJ) in cancer patients who take bone-modifying agents to reduce the risk for skeletal events associated with bone metastases. One of the studies, S0702, was a prospective observa...

Fast Five Quiz: How Much Do You Know About Metastatic Bone Disease?
https://reference.staging.medscape.com/viewarticle/912319

May 19th, 2019 - Metastatic bone disease is a secondary cancer that occurs when cells from the primary tumor migrate to a bone location. Cell migration can occur by attachment to a basement membrane of the blood vessel wall (ie, neovascularization) or migration to...

Fast Five Quiz: How Much Do You Know About Metastatic Bone Disease?
https://reference.medscape.com/viewarticle/912319_2

May 19th, 2019 - Figure 1. Imaging of metastatic bone disease showing multiple metastases to the shoulder, ribs, pelvis, humerus, femur and spinal vertebrae. The most common location for metastatic bone disease is the spine, regardless of the primary tumor locatio...

Fast Five Quiz: How Much Do You Know About Metastatic Bone Disease?
https://reference.medscape.com/viewarticle/912319

May 19th, 2019 - Metastatic bone disease is a secondary cancer that occurs when cells from the primary tumor migrate to a bone location. Cell migration can occur by attachment to a basement membrane of the blood vessel wall (ie, neovascularization) or migration to...

Fast Five Quiz: Metastatic Bone Disease Management
https://reference.medscape.com/viewarticle/906277_2

Mar 26th, 2019 - Answer 1/5 In which of the following primary cancers does MBD most commonly occur? Your peers chose: In men, liver and kidney cancers; in women, uterine and thyroid cancers 0% In men, kidney and brain cancers; in women, liver and kidney cancers 0%...

see more →